Invesco India Pharma and Healthcare Fund NFO is open for subscription. 7 key details to know
1/7
New pharma fund
Invesco India Mutual Fund has launched Invesco India Pharma and Healthcare Fund, which is open for subscription and will close on September 1.
2/7
Investment universe
The scheme will invest across pharmaceutical companies, hospitals, diagnostics, contract development and manufacturing organizations (CDMOs), contract research organizations (CROs), medical devices, healthcare services, insurance and other allied healthcare segments.
3/7
Benchmark and fund manager
The fund will be managed by Aditya Khemani and will be benchmarked against the BSE Healthcare TRI.
Amazon Top Deals
POWERED BY
Crompton Ozone 75 Litres Desert Air Cooler for home | Large & Easy Clean Ice Chamber | 4-Way Air Deflection | High Density Honeycomb Pads | Everlast Pump | Auto Fill| 3 Year Brand Warranty
₹9,798Buy Now43%
OFF
LG 32 L Convection Microwave Oven (MC3286BRUM, Black, 360° Motorised Rotisserie for Bar-be-queing, 301 Auto Cook Menu, Stainless steel cavity, Indian Cuisine, Tandoor Se, Steam Clean & Diet Fry)
₹19,090Buy Now20%
OFF
4/7
Minimum investment
The minimum lumpsum investment amount during the NFO is Rs 1,000 and in multiples of Re 1 thereafter. For SIP investments, the minimum application amount is Rs 100 and in multiples of Re 1 thereafter.
5/7
Exit load
The fund will charge an exit load of 0.50% for units redeemed/switched out on or before 3 months from the date of allotment. No exit load will be charged if units are redeemed/switched out after 3 months.
6/7
What fund manager say
"India's healthcare sector is undergoing a structural transformation. The country is not only witnessing rising healthcare consumption driven by favourable demographics and increasing affordability but is also strengthening its position as a global pharmaceutical and healthcare innovation hub,” said Aditya Khemani, Head of Equity & Fund Manager, Invesco Mutual Fund.
7/7
Way ahead
“We see attractive opportunities across domestic pharma, hospitals, diagnostics, CDMOs and emerging healthcare segments that can potentially benefit from this multi-year growth cycle. Our investment approach will focus on identifying quality businesses with sustainable competitive advantages and strong growth visibility across the healthcare ecosystem,” Khemani further said.